TheProfitWatch

DNLI - Denali Therapeutics Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
15.79 0.54 (3.42%) --- --- --- 0.01 (0.06%) 1.1 (7.22%) 0.03 (0.2%) 0.55 (3.61%)

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Closed

Earnings & Ratios

Basic EPS:
-0.72
Diluted EPS:
-0.72
Basic P/E:
-22.6806
Diluted P/E:
-22.6806
RSI(14) 1m:
64.86
VWAP:
16.32
RVol:
0.6812

Events

Period Kind Movement Occurred At

Related News